Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Egetis Therapeutics AB (publ) (P0F.F)

Compare
0.2955
-0.0145
(-4.68%)
At close: April 15 at 9:00:34 PM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
46,100
46,100
57,600
22,500
38,300
Cost of Revenue
11,600
11,600
11,000
142,600
96,600
Gross Profit
34,500
34,500
46,600
-120,100
-58,300
Operating Expense
363,900
363,900
371,300
77,000
46,800
Operating Income
-329,400
-329,400
-324,700
-197,100
-105,100
Net Non Operating Interest Income Expense
-9,400
-9,400
700
800
-100
Pretax Income
-343,200
-343,200
-326,800
-193,800
-104,500
Tax Provision
300
300
100
--
--
Net Income Common Stockholders
-343,600
-343,600
-326,900
-193,800
-104,500
Diluted NI Available to Com Stockholders
-343,600
-343,600
-326,900
-193,800
-104,500
Basic EPS
-1.10
-1.10
-1.30
-1.00
-0.60
Diluted EPS
-1.10
-1.10
-1.30
-1.00
-0.60
Basic Average Shares
306,537.4240
306,537.4240
256,752.2820
194,238.2100
179,906.4570
Diluted Average Shares
310,902.9260
310,902.9260
260,011.4780
194,238.2100
179,906.4570
Total Operating Income as Reported
-329,400
-329,400
-324,800
-198,100
-105,700
Total Expenses
375,500
375,500
382,300
219,600
143,400
Net Income from Continuing & Discontinued Operation
-343,600
-343,600
-326,900
-193,800
-104,500
Normalized Income
-340,027
-340,027
-324,756.2000
-193,800
-104,500
Interest Income
16,500
16,500
4,900
900
100
Interest Expense
25,900
25,900
4,200
100
200
Net Interest Income
-9,400
-9,400
700
800
-100
EBIT
-317,300
-317,300
-322,600
-193,700
-104,300
EBITDA
-317,300
-317,300
-322,600
-191,000
-101,800
Reconciled Cost of Revenue
11,600
11,600
11,000
142,600
96,600
Reconciled Depreciation
--
--
3,600
2,700
2,500
Net Income from Continuing Operation Net Minority Interest
-343,600
-343,600
-326,900
-193,800
-104,500
Total Unusual Items Excluding Goodwill
-4,500
-4,500
-2,700
--
--
Total Unusual Items
-4,500
-4,500
-2,700
--
--
Normalized EBITDA
-312,800
-312,800
-319,900
-191,000
-101,800
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
--
Tax Effect of Unusual Items
-927
-927
-556.2000
--
--
12/31/2021 - 2/6/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARDX.MX Ardelyx, Inc.
105.50
0.00%
 
B9A.F BioArctic AB (publ)
16.79
+12.46%
 
HQ1.MU Oruka Therapeutics Inc. R
7.05
+6.02%
 
RPD.MU Royalty Pharma plc
28.20
0.00%
 
BT3.BE Lineage Cell Therapeutics Inc
0.3800
-5.47%
 
7PO.F Poxel S.A.
0.4510
-11.39%
 
05Y.MU Vivoryon Therapeutics NV
1.7440
-4.49%
 
PROT Proteonomix, Inc.
0.0000
0.00%
 
ICY.HA Incyte Corp
52.14
+1.76%
 
2HA.F Spero Therapeutics, Inc.
0.6170
+16.64%